Therapy-resistant breast cancer in focus: Clinically relevant mitigation by flavonoids targeting cancer stem cells.
breast cancer
cancer stem cells
non-responsiveness
predictive
preventive and personalised medicine
resistance
secondary and tertiary care
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2023
2023
Historique:
received:
06
02
2023
accepted:
27
03
2023
medline:
24
4
2023
pubmed:
24
4
2023
entrez:
24
04
2023
Statut:
epublish
Résumé
Significant limitations of the reactive medical approach in breast cancer management are clearly reflected by alarming statistics recorded worldwide. According to the WHO updates, breast malignancies become the leading cancer type. Further, the portion of premenopausal breast cancer cases is permanently increasing and demonstrates particularly aggressive patterns and poor outcomes exemplified by young patients with triple-negative breast cancer that lacks targeted therapy. Accumulating studies suggest the crucial role of stem cells in tumour biology, high metastatic activity, and therapy resistance of aggressive breast cancer. Therefore, targeting breast cancer stem cells is a promising treatment approach in secondary and tertiary breast cancer care. To this end, naturally occurring substances demonstrate high potential to target cancer stem cells which, however, require in-depth analysis to identify effective anti-cancer agents for cost-effective breast cancer management. The current article highlights the properties of flavonoids particularly relevant for targeting breast cancer stem cells to mitigate therapy resistance. The proposed approach is conformed with the principles of 3P medicine by applying predictive diagnostics, patient stratification and treatments tailored to the individualised patient profile. Expected impacts are very high, namely, to overcome limitations of reactive medical services improving individual outcomes and the healthcare economy in breast cancer management. Relevant clinical applications are exemplified in the paper.
Identifiants
pubmed: 37089930
doi: 10.3389/fphar.2023.1160068
pii: 1160068
pmc: PMC10115970
doi:
Types de publication
Systematic Review
Langues
eng
Pagination
1160068Informations de copyright
Copyright © 2023 Mazurakova, Koklesova, Vybohova, Samec, Kudela, Biringer, Šudomová, Hassan, Kello, Büsselberg, Golubnitschaja, Kubatka.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nutr Cancer. 2017 Oct;69(7):1088-1098
pubmed: 28976208
Proc Natl Acad Sci U S A. 2016 Apr 5;113(14):E2047-56
pubmed: 27001847
Stem Cell Res Ther. 2013;4(6):146
pubmed: 24331293
Pharmaceuticals (Basel). 2019 Jan 10;12(1):
pubmed: 30634637
J Transl Med. 2011 Dec 07;9:209
pubmed: 22152097
Semin Cancer Biol. 2020 Dec;67(Pt 1):74-82
pubmed: 31412296
EPMA J. 2021 Oct 06;12(4):559-587
pubmed: 34950252
EPMA J. 2022 May 12;13(2):177-193
pubmed: 35578648
FEBS J. 2017 Jun;284(12):1830-1854
pubmed: 28398698
Am J Clin Nutr. 2009 Mar;89(3):905-12
pubmed: 19158208
Mol Divers. 2022 Dec;26(6):3225-3240
pubmed: 35129762
Mol Med Rep. 2015 Jun;11(6):4297-302
pubmed: 25647733
Biomed Pharmacother. 2017 Sep;93:1285-1291
pubmed: 28747003
Med Res Rev. 2020 Sep;40(5):2049-2084
pubmed: 32525247
Int J Pharm. 2019 Oct 30;570:118642
pubmed: 31446024
Int J Mol Sci. 2021 Apr 20;22(8):
pubmed: 33924032
Cancers (Basel). 2011 Apr 19;3(2):2106-30
pubmed: 24212798
J Hum Nutr Diet. 2015 Jun;28(3):272-82
pubmed: 24646362
J Egypt Natl Canc Inst. 2022 Dec 12;34(1):51
pubmed: 36504339
Life Sci. 2019 Oct 15;235:116797
pubmed: 31472146
Cancers (Basel). 2018 Dec 28;11(1):
pubmed: 30597838
Pregnancy Hypertens. 2022 Aug;29:72-85
pubmed: 35803199
Cancers (Basel). 2021 Jan 03;13(1):
pubmed: 33401572
Clin Transl Oncol. 2020 Sep;22(9):1619-1634
pubmed: 32056127
Eur J Pharmacol. 2017 Jan 5;794:127-134
pubmed: 27845065
Aging Cell. 2017 Dec;16(6):1208-1218
pubmed: 28994177
Oncotarget. 2014 Jun 15;5(11):3743-55
pubmed: 25003837
Oncotarget. 2017 Aug 10;8(43):74391-74405
pubmed: 29088795
Biomed Pharmacother. 2017 Dec;96:1465-1477
pubmed: 29198744
Nutrition. 2015 Apr;31(4):560-9
pubmed: 25770318
Oncol Lett. 2021 Aug;22(2):620
pubmed: 34267813
Molecules. 2020 Apr 21;25(8):
pubmed: 32326231
SLAS Discov. 2020 Aug;25(7):734-743
pubmed: 32484006
EXCLI J. 2020 May 13;19:627-634
pubmed: 32536833
Food Chem. 2022 Jul 30;383:132531
pubmed: 35413752
Clin Cosmet Investig Dermatol. 2022 Sep 12;15:1883-1897
pubmed: 36117768
Life Sci. 2020 Jun 1;250:117591
pubmed: 32224026
J Ethnopharmacol. 2018 Jan 10;210:296-310
pubmed: 28864169
Free Radic Biol Med. 2021 Jun;169:238-247
pubmed: 33892113
Oncotarget. 2016 Jan 5;7(1):771-85
pubmed: 26506421
Nutrients. 2013 Aug 28;5(9):3367-87
pubmed: 23989753
Cells. 2021 Jan 06;10(1):
pubmed: 33419140
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Saudi Pharm J. 2021 Jan;29(1):12-26
pubmed: 33603536
Oncogene. 2011 May 5;30(18):2161-72
pubmed: 21242971
Oncol Rep. 2018 Dec;40(6):3752-3762
pubmed: 30272295
EPMA J. 2022 Apr 14;13(2):315-334
pubmed: 35437454
Biosci Biotechnol Biochem. 2018 Apr;82(4):600-610
pubmed: 29504827
J Biol Chem. 2008 Jun 20;283(25):17635-51
pubmed: 18441325
EPMA J. 2020 Aug 10;11(3):505-515
pubmed: 32839667
Cell Death Discov. 2018 Nov 20;4:105
pubmed: 30479839
Molecules. 2020 Mar 19;25(6):
pubmed: 32204409
Nutrients. 2017 Jul 18;9(7):
pubmed: 28718813
ACS Omega. 2020 May 14;5(20):11849-11872
pubmed: 32478277
Nutrients. 2019 Mar 14;11(3):
pubmed: 30875792
Cancer. 2016 Aug 15;122(16):2544-51
pubmed: 27183356
Pathol Res Pract. 2022 Sep;237:154029
pubmed: 35961057
Oncotarget. 2015 Apr 10;6(10):8167-84
pubmed: 25717032
Phytother Res. 2019 Feb;33(2):379-386
pubmed: 30479044
Phytother Res. 2018 Aug;32(8):1530-1536
pubmed: 29635751
Int J Mol Sci. 2020 Dec 26;22(1):
pubmed: 33375383
J Hum Nutr Diet. 2010 Dec;23(6):590-600
pubmed: 20807303
J Cell Mol Med. 2017 Nov;21(11):2837-2851
pubmed: 28524540
Stem Cell Investig. 2020 Nov 03;7:20
pubmed: 33294429
J Cancer Res Clin Oncol. 2019 May;145(5):1087-1109
pubmed: 30903319
Molecules. 2021 Oct 26;26(21):
pubmed: 34770867
Int J Mol Sci. 2021 Apr 25;22(9):
pubmed: 33923053
Am J Clin Nutr. 2013 Dec;98(6):1493-501
pubmed: 24153343
Cell Mol Biol Lett. 2018 Mar 22;23:12
pubmed: 29588647
Curr Pharm Des. 2015;21(10):1301-10
pubmed: 25506895
EXCLI J. 2018 Aug 27;17:856-863
pubmed: 30233284
Molecules. 2016 Dec 28;22(1):
pubmed: 28036030
Anticancer Res. 2019 Jun;39(6):2821-2827
pubmed: 31177119
Front Oncol. 2019 Oct 16;9:1003
pubmed: 31681564
Toxicol Rep. 2022 Mar 06;9:382-392
pubmed: 35299871
Diabetes Metab Syndr Obes. 2021 Jan 27;14:387-397
pubmed: 33536772
Biochem Biophys Res Commun. 2014 Oct 10;453(1):112-6
pubmed: 25261721
EPMA J. 2018 Apr 11;9(2):175-186
pubmed: 29896316
Med Sci Monit. 2018 Jan 21;24:412-420
pubmed: 29353288
Evid Based Complement Alternat Med. 2017;2017:1053617
pubmed: 28947908
Aging (Albany NY). 2022 Dec 22;14(24):9877-9889
pubmed: 36566021
Nutr Cancer. 2021;73(5):845-855
pubmed: 32482103
Molecules. 2019 Mar 04;24(5):
pubmed: 30836718
Clin Nutr ESPEN. 2022 Dec;52:158-168
pubmed: 36513449
BMC Complement Med Ther. 2020 Nov 25;20(1):366
pubmed: 33238963
Cancer Prev Res (Phila). 2017 Jun;10(6):363-370
pubmed: 28400479
Oxid Med Cell Longev. 2021 Jul 19;2021:3268136
pubmed: 34336089
Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):E9066-E9075
pubmed: 29073103
Onco Targets Ther. 2015 Jun 03;8:1327-34
pubmed: 26082649
Breast. 2022 Dec;66:15-23
pubmed: 36084384
Molecules. 2019 Mar 15;24(6):
pubmed: 30875891
Curr Mol Med. 2011 Jun;11(4):270-85
pubmed: 21506923
Clin Exp Med. 2020 May;20(2):173-190
pubmed: 32016615
Curr Mol Med. 2012 Feb;12(2):163-76
pubmed: 22280355
Biomed Pharmacother. 2019 Apr;112:108612
pubmed: 30798142
EPMA J. 2017 Mar 8;8(1):17-22
pubmed: 28620440
Sci Rep. 2021 Feb 5;11(1):3214
pubmed: 33547369
Pharmaceuticals (Basel). 2021 Aug 12;14(8):
pubmed: 34451892
J Natl Cancer Inst. 2014 Sep 04;106(9):
pubmed: 25190728
Tumour Biol. 2019 Aug;41(8):1010428319869101
pubmed: 31423948
Toxicol Appl Pharmacol. 2022 Feb 15;437:115887
pubmed: 35063459
Int J Mol Sci. 2021 Aug 11;22(16):
pubmed: 34445360
J Nutr Sci. 2016 Dec 29;5:e47
pubmed: 28620474
Eur J Nutr. 2016 Apr;55(3):955-65
pubmed: 25930965
EPMA J. 2021 Aug 17;12(3):243-264
pubmed: 34422142
Cancer Prev Res (Phila). 2012 Feb;5(2):309-19
pubmed: 22307566
J Cancer Res Clin Oncol. 2020 Dec;146(12):3079-3096
pubmed: 32902794
Biomolecules. 2021 Jun 16;11(6):
pubmed: 34208562
Biomolecules. 2019 Jul 18;9(7):
pubmed: 31323834
Cancers (Basel). 2019 Nov 14;11(11):
pubmed: 31739537
Int Immunopharmacol. 2017 Mar;44:1-8
pubmed: 27998743
EPMA J. 2022 Jul 8;13(3):461-486
pubmed: 35821883
Antioxidants (Basel). 2017 May 05;6(2):
pubmed: 28475126
Mini Rev Med Chem. 2011 Apr;11(4):298-344
pubmed: 21428901
Oncotarget. 2016 Jul 26;7(30):48607-48613
pubmed: 27224910
Cancers (Basel). 2020 Jun 08;12(6):
pubmed: 32521759
EPMA J. 2017 May 2;8(2):141-157
pubmed: 28725292
Phytochemistry. 2006 Sep;67(17):1849-55
pubmed: 16876833
Int J Mol Sci. 2021 Aug 27;22(17):
pubmed: 34502188
Oncologist. 2017 Apr;22(4):386-393
pubmed: 28242790
Cancer J. 2021 Jan-Feb 01;27(1):8-16
pubmed: 33475288
Front Pharmacol. 2019 Dec 06;10:1336
pubmed: 31866857
PLoS One. 2014 Feb 13;9(2):e89021
pubmed: 24551210
Methods Mol Biol. 2018;1692:89-95
pubmed: 28986889
Cancers (Basel). 2020 Dec 14;12(12):
pubmed: 33327542
EPMA J. 2021 May 17;12(2):155-176
pubmed: 34025826
Mol Carcinog. 2015 Nov;54(11):1494-502
pubmed: 25154499
Stem Cells. 2012 May;30(5):833-44
pubmed: 22489015